retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Retatrutide, a GIP, and receptor Retatrutide Explained: The Triple Agonist

The combination addresses fat loss from both directions: reduced caloric intake via appetite control and enhanced fat breakdown at the cellular level

Taking progress photos and maintaining brief daily notes helps identify changes that accumulate slowly

In those cases, prompt discontinuation and urgent care are essential

supplements GLP-1 medications like semaglutide ( Ozempic and Wegovy) and tirzepatide ( Zepbound and Mounjaro) are FDA-approved prescription drugs specifically designed to manage type 2 diabetes and/or aid in weight loss

The 4mg dose remains a reasonable target for those who can't tolerate higher doses while still producing clinically significant weight loss